Carol_Meschter Blog

CBI

Histopathology on Human Muscle Biopsies from patients affected with a Glycogen Storage Disease

By On November 14, 2018

Provided are thin EPON sections with our unique PAS staining and TEM photomicrographs of patient skeletal muscle with abnormal lysosomes.   Glycogen Storage Diseases are devastating, rare genetic orphan diseases for which… Read More

CBI

Models of Pulmonary Infection

By On July 3, 2018

  CBI has optimized and validated four new pulmonary models that have both immune mediated and infection components.   Model of Nasal Aspergillosis in Rabbits Chronic invasive fungal rhinosinusitis (Aspergillus fumigatus)may occur… Read More

Cannabis Pharmacology

Cannabis Preclinical Pharmacology and Toxicology

By On March 14, 2018

Cannabis Toxicology and Pharmacology             Assessment of Cannabis Products for Purity, Effectiveness and Safety. Now that medical cannabis has achieved some degree of legality and public acceptability,… Read More

CBI

CBI Sponsors Ototoxicity and ABRs in Toxicologic Assessments at the ACT

By On March 2, 2018

The ACT Annual Meeting is the most cutting edge toxicology meeting anywhere!  This year scientists from CBI attended and exhibited at the ACT meeting in Palm Springs CA in November 4-9, 2o17. … Read More

Uncategorized

New Blog.mr

By On March 2, 2018

Read More

CBI

Scleroderma: Tight Skin Mouse Model at CBI

By On October 17, 2017

CBI offers preclinical research studies in dermal and pulmonary fibrosis.  In addition to our validated bleomycin-induced fibrosis models, we also now offer fibrosis studies with the JAX Tight Skin Mouse Model. There… Read More

Uncategorized

Toxicologic and Histopathologic Peer Review

By On August 28, 2017

Histopathologic Peer Review (PR) is an important tool in aiding quality and accuracy in the histopathologic assessment of toxicology studies. The peer review verifies and improves the accuracy and quality of pathology… Read More

CBI

The (Non)Reproducibility Crisis, Part 4

By On August 18, 2017

Harris cites numerous examples of Type I error (also known as false positives) in efficacy studies throughout the book—i.e., drugs that worked in disease models but then failed in human trials.  Chapter… Read More

CBI

The (Non)Reproducibility Crisis, Part 3

By On August 9, 2017

In our previous post, we discussed NPR science journalist Richard Harris’s general critique of animal research in his book Rigor Mortis, but there is more to be said.  If animal models are… Read More

CBI

The (Non)Reproducibility Crisis, Part 2

By On August 2, 2017

In Part 1 of this series, we gave a general introduction to the problem of non-reproducibility of preclinical studies and some reasons why CROs including Comparative Biosciences are somewhat immune to it.… Read More